Vir, Morgan Stanley

Morgan Stanley Doubles Vir Biotechnology Price Forecast - Here's Why
Vir Biotechnology's Phase 1 data highlights early promise for T-cell engagers targeting HER2-positive tumors and prostate cancer with manageable safety.
Morgan Stanley Sees 67% Upside Potential for Vir Biotechnology Stock
Morgan Stanley has upgraded Vir Biotechnology ( VIR, Financial) and uplifted its price target for the stock to $20 from "Equal-weight" to "Overweight," sending the stock sharply higher. The stock is currently trading near $12, which suggests it has a 67% upside potential from Morgan's price target of $20.
Vir Biotechnology (NASDAQ:VIR) Upgraded at Morgan Stanley
Morgan Stanley upgraded shares of Vir Biotechnology (NASDAQ:VIR – Free Report) from an equal weight rating to an overweight rating in a report released on Thursday morning,Benzinga reports. They currently have $20.
Vir Biotechnology Stock Soars On Prostate Cancer Trial Data - Here's Why
Vir Biotechnology's Phase 1 trials reveal promising safety and efficacy for dual-masked T-cell engagers targeting HER2 and PSMA in cancer therapies.
Vir Biotech Shares Rise on Positive Data for Cancer Treatments
Vir Biotechnology shares were up 67% to $13.15 after the company reported encouraging initial Phase 1 data for its dual-masked T-cell engagers, VIR-5818 and VIR-5500. The clinical-stage biopharmaceutical company said VIR-5818 targets HER2-expressing solid tumors,
Vir Biotechnology upgraded to Overweight from Equal Weight at Morgan Stanley
Morgan Stanley analyst Michael Ulz upgraded Vir Biotechnology (VIR) to Overweight from Equal Weight with a price target of $20, up from $10.
Gilead upgraded by Morgan Stanley on lenacapavir potential
Morgan Stanley has upgraded Gilead Sciences (NASDAQ:GILD) to overweight from equal weight, citing the company's HIV drug lenacapavir. The investment bank said it was "leaning into the bull case," seeing "the potential for upward estimate revisions on lenacapavir for PrEP and further multiple expansion as the company makes progress with its
Morgan Stanley upgrades Gilead on HIV treatment growth
Morgan Stanley upgraded Gilead Sciences Inc (NASDAQ:GILD) to "overweight" from "equal weight," raising its price target to $113 from $87 on HIV prevention drug Lenacapavir (PrEP) and next-gen HIV treatments.
Vir Biotechnology’s (VIR) “Buy” Rating Reiterated at HC Wainwright
Vir Biotechnology (NASDAQ:VIR – Get Free Report)‘s stock had its “buy” rating reaffirmed by analysts at HC Wainwright in a ...
Analysts Offer Insights on Healthcare Companies: Iovance Biotherapeutics (IOVA) and Vir Biotechnology (VIR)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Iovance Biotherapeutics (IOVA – Research Report) ...
Hosted on MSN3d
VIR Stock Up on Early Safety & Efficacy Data on Two Cancer Candidates
Vir Biotechnology, Inc. VIR announced encouraging initial data from a phase I study that evaluated its investigational ...
Vir Biotechnology Reports Positive Phase 2 Results, Shares Surge by 58%
Following the publication of encouraging results from Phase 2 studies for two investigational cancer treatments, Vir ...
Vir Biotechnology: A Rocket Off Phase 1 Data... What Could Go Wrong?
Vir Biotechnology's recent share price rally is driven by their promising cancer program. Having shot to over a $1.5B market ...
Vir Biotechnology’s Early Stage Developments and Valuation Lead to Hold Rating Amid Long-Term Promise and Near-Term Uncertainties
Eric Joseph, an analyst from J.P. Morgan, maintained the Hold rating on Vir Biotechnology (VIR – Research Report). The associated price target ...